Asklepios Klinik Altona

Running trials

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

  NCT07176312· Phase 2· Source

• Active, not recruiting

  WATCHMAN FLX Pro European Registry

  NCT07262255· Source

• Recruiting

  Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

  NCT06607458· Phase 2· Source

• Recruiting

  VASC-AF Study: Vascular Closure vs Manual Compression

  NCT07414121· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Source

• Recruiting

  COCONUT Study Concomitant PVI and LAAC

  NCT06861673· Source

• Recruiting

  Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

  NCT05976685· Source

• Active, not recruiting

  Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

  NCT05948475· Phase 3· Source

• Recruiting

  Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI

  NCT05786131· Source

• Active, not recruiting

  A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

  NCT05827016· Phase 3· Source

• Active, not recruiting

  A Study of Daratumumab

  NCT05438043· Phase 3· Source

• Recruiting

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  NCT04628026· Phase 3· Source

• Recruiting

  ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  NCT05059444· Source

• Recruiting

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  NCT04585750· Phase 1/2· Source

• Recruiting

  Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.

  NCT04298723· Source

• Active, not recruiting

  Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

  NCT04230759· Phase 2· Source

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Source

• Recruiting

  Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation

  NCT04240366· Source

• Active, not recruiting

  Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

  NCT03897127· Phase 3· Source

• Active, not recruiting

  Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

  NCT03647878· Source

• Recruiting

  BAROSTIM THERAPY™ In Resistant Hypertension

  NCT02880631· Source

• Recruiting

  BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

  NCT02880618· Source

• Active, not recruiting

  A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

  NCT02912949· Phase 2· Source

• Recruiting

  Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

  NCT01252485· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation5 recruiting
• Colorectal cancer3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Endometrial cancer2 recruiting
• Head and neck cancer2 recruiting
• Lung cancer2 recruiting
• Multiple myeloma2 recruiting
• Ovarian cancer2 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Source

• Completed

  A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

  NCT05383352· Phase 1· Source

• Completed

  Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

  NCT04813627· Source

• Active, not recruiting

  A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

  NCT04486378· Phase 2· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Source

• Completed

  MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

  NCT04495621· Phase 1/2· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Source

• Completed

  Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

  NCT04221529· Phase 2· Source

• Active, not recruiting

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· Phase 3· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Source

• Completed

  A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565· Phase 2· Source

• Completed

  A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  NCT03267316· Phase 1/2· Source

• Completed

  BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

  NCT02876042· Source